Labtech International, a distributor of life science instrumentation in the UK and France, has agreed to provide a global sales and marketing support service for the G-Storm PCR machines that target the international life science research market.
The agreement allows Agilegene Technologies, the UK manufacturer of the G-Storm PCR machines, to focus solely on engineering and software development of future products.
With 19 years of sales and marketing experience in the life science instrumentation sector, Labtech International, based in Ringmer, Sussex, is suitably equipped to offer G-Storm's global distributors and customers a high-quality sales support service.
The G-Storm thermal cyclers in a striking new black livery are purpose-built to meet the demands of molecular biology. The G-Storm touch-screen user interface is easy to use and makes programming, file management and cycler control a simple process.
Labtech to support G-Storm PCR machines
G-Storm machines are given a new black livery
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
How intelligent checkweighers offer improved productivity in pharmaceutical manufacturing
Read morePrecise weighing, automated reporting and tailored handling help pharmaceutical producers reduce waste, streamline compliance processes and maintain reliable output across demanding production lines
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more.
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
![How intelligent checkweighers offer improved productivity in pharmaceutical manufacturing]()
How intelligent checkweighers offer improved productivity in pharmaceutical manufacturing
Precise weighing, automated reporting and tailored handling help pharmaceutical producers reduce waste, streamline compliance processes and maintain reliable output across demanding production lines
Manufacturing
![Shilpa CDMO invests $50m to expand peptide manufacturing capacity in India]()
Shilpa CDMO invests $50m to expand peptide manufacturing capacity in India
The CDMO is investing $50m in additional solid-phase peptide synthesis capacity and a new commercial manufacturing line at its Raichur campus, expanding its capabilities to meet demand for GLP-1s and increasingly complex peptide therapeutics across oncology and rare diseases
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
![From speed to strategy: how UK life sciences should respond to China’s rise]()
From speed to strategy: how UK life sciences should respond to China’s rise
A group of biotech founders, big pharma leaders, clinical and CMC specialists, and CDMO executives gathered at a recent dinner sponsored by AsymChem to discuss a question now sitting in many boardrooms: what is China’s maturing biopharma ecosystem doing to the global industry, and how should UK companies respond?
